Project description
Selectively enhancing antibodies through light irradiation
Monoclonal antibodies have been considered a significant weapon against cancer since the beginning of the 20th century. After decades of research, medicine has managed to eliminate their adverse reactions to patients and develop revolutionary cancer therapies. The EU-funded ALISE project will focus on the possibility of boosting the anticancer activity only in tumours. To this aim, researchers will design and synthesise light-controllable conjugates of monoclonal antibodies with peptides whose anticancer activity can be enhanced in tumours by irradiation with light. In this project, seven leading institutions with significant expertise, resources and knowledge on design, synthesis and preclinical study in this field will join forces to contribute to innovative and safer therapeutic strategies.
Fields of science
Programme(s)
Coordinator
02094 Kyiv
Ukraine
See on map
Participants (6)
76131 Karlsruhe
See on map
CB2 1TN Cambridge
See on map
LV-1006 Riga
See on map
03022 Kiyv
See on map
76227 Karlsruhe
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1081 HV Amsterdam
See on map